Skip to main content
SpringerLink
Log in

Mucins and Cytokeratins as Serum Tumor Markers in Breast Cancer

  • Chapter
Advances in Cancer Biomarkers

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 867))

Abstract

Structural and functional characteristics of mucins and cytokeratins are shortly described. Thereafter, those commonly used in breast cancer as serum tumor markers are considered. First CA15.3, MCA, CA549, CA27.29 mucins and CYFRA21.1, TPA, TPS cytokeratins alone or in association have been examined in different stages and conditions. Then their usefulness in monitoring disease-free breast cancer patients is evaluated. The central role of the established cut-off and critical change, the “early” treatment of recurrent disease and the potential benefit in survival are other issues that have been highlighted and discussed. The successive sections and subsections deal with the monitoring of advanced disease. In them, the current recommendations and the principal findings on using the above mentioned mucins and cytokeratins have been reported. A computer program for interpreting consecutive measurements of serum tumor markers also has been illustrated. The final part of the chapter is devoted to mucins and cytokeratins as markers of circulating and disseminated tumor cells and their usefulness for prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK (2011) Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta 1815(2):224–240

    PubMed Central  CAS  PubMed  Google Scholar 

  2. Hatzfeld M, Franke WW (1985) Pair formation and promiscuity of cytokeratins: formation in vitro of heterotypic complexes and intermediate-sized filaments by homologous and heterologous recombinations of purified polypeptides. J Cell Biol 101(5 Pt 1):1826–1841

    Article  CAS  PubMed  Google Scholar 

  3. Schweizer J, Bowden PE, Coulombe PA, Langbein L, Lane EB, Magin TM, Maltais L, Omary MB, Parry DA, Rogers MA, Wright MW (2006) New consensus nomenclature for mammalian keratins. J Cell Biol 174(2):169–174

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Laakso M, Loman N, Borg A, Isola J (2005) Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 18(10):1321–1328

    Article  CAS  PubMed  Google Scholar 

  5. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R (1982) The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31(1):11–24

    Article  CAS  PubMed  Google Scholar 

  6. Boecker W, Buerger H, Schmitz K, Ellis IA, van Diest PJ, Sinn HP, Geradts J, Diallo R, Poremba C, Herbst H (2001) Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol 195(4):415–421

    Article  CAS  PubMed  Google Scholar 

  7. Chu PG, Weiss LM (2002) Keratin expression in human tissues and neoplasms. Histopathology 40(5):403–439

    Article  CAS  PubMed  Google Scholar 

  8. Malzahn K, Mitze M, Thoenes M, Moll R (1998) Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 433(2):119–129

    Article  CAS  PubMed  Google Scholar 

  9. Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest PJ, Brandt B, Boecker W, Buerger H (2002) Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82(11):1525–1533

    Article  CAS  PubMed  Google Scholar 

  10. Boecker W, Buerger H (2003) Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif 36(Suppl 1):73–84

    Article  PubMed  Google Scholar 

  11. Wetzels RH, Kuijpers HJ, Lane EB, Leigh IM, Troyanovsky SM, Holland R, van Haelst UJ, Ramaekers FC (1991) Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol 138(3):751–763

    PubMed Central  CAS  PubMed  Google Scholar 

  12. Birnbaum D, Bertucci F, Ginestier C, Tagett R, Jacquemier J, Charafe-Jauffret E (2004) Basal and luminal breast cancers: basic or luminous? (review). Int J Oncol 25(2):249–258

    CAS  PubMed  Google Scholar 

  13. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752

    Article  CAS  PubMed  Google Scholar 

  14. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203(2):661–671

    Article  PubMed  Google Scholar 

  15. Bánkfalvi A, Ludwig A, De-Hesselle B, Buerger H, Buchwalow IB, Boecker W (2004) Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases. Mod Pathol 17(9):1051–1061

    Article  PubMed  Google Scholar 

  16. Boecker W, Moll R, Dervan P, Buerger H, Poremba C, Diallo RI, Herbst H, Schmidt A, Lerch MM, Buchwalow IB (2002) Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol 198(4):458–467

    Article  PubMed  Google Scholar 

  17. Tobias R, Rothwell C, Wagner J, Green A, Liu YS (1985) Development and evaluation of a radioimmunoassay for the detection of a monoclonal antibody defined breast tumor-associated antigen 115D8/DF3. Clin Chem 31:986

    Google Scholar 

  18. Bray KR, Koda JE, Gaur PK (1987) Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker. Cancer Res 47(22):5853–5860

    CAS  PubMed  Google Scholar 

  19. Sawant SS, Zingde SM, Vaidya MM (2008) Cytokeratin fragments in the serum: their utility for the management of oral cancer. Oral Oncol 44(8):722–732

    Article  CAS  PubMed  Google Scholar 

  20. Bjorklund B, Bjorklund V (1957) Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique; presence of an insoluble, heat-labile tumor antigen. Int Arch Allergy Appl Immunol 10(3):153–184

    Article  CAS  PubMed  Google Scholar 

  21. Sundström BE, Stigbrand TI (1994) Cytokeratins and tissue polypeptide antigen. Int J Biol Markers 9(2):102–108

    PubMed  Google Scholar 

  22. Bonfrer JM, Groeneveld EM, Korse CM, van Dalen A, Oomen LC, Ivanyi D (1994) Monoclonal antibody M3 used in tissue polypeptide-specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18. Tumour Biol 15(4):210–222

    Article  CAS  PubMed  Google Scholar 

  23. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr (2008) The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108(2):402–408

    Article  CAS  PubMed  Google Scholar 

  24. Molina R, Auge JM, Escudero JM, Marrades R, Viñolas N, Carcereny E, Ramirez J, Filella X (2008) Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol 29(6):371–380

    Article  CAS  PubMed  Google Scholar 

  25. Filella X, Cases A, Molina R, Jo J, Bedini JL, Revert L, Ballesta AM (1990) Tumor markers in patients with chronic renal failure. Int J Biol Markers 5(2):85–88

    CAS  PubMed  Google Scholar 

  26. Szekanecz E, Szucs G, Szekanecz Z, Tarr T, Antal-Szalmás P, Szamosi S, Szántó J, Kiss E (2008) Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices. J Autoimmun 31(4):372–376

    Article  CAS  PubMed  Google Scholar 

  27. Wong RC, Klingberg S, Wilson R (2002) CA15-3 and cancer associated serum antigenassays are alternatives to the KL-6 assay for measuring serum MUC-1 levels in patients with interstitial lung disease associated with polymyositis/dermatomyositis. J Rheumatol 29(9):2021–2022

    PubMed  Google Scholar 

  28. Okada M, Suzuki K, Nakanishi T, Nakashima M (2006) Serum levels of KL-6 are positively correlated with those of CA15-3 in patients with interstitial pneumonia associated with collagen diseases. Respirology 11(4):509–510

    Article  PubMed  Google Scholar 

  29. Symeonidis A, Kouraklis-Symeonidis A, Apostolopoulos D, Arvanitopoulou E, Giannakoulas N, Vassilakos P, Zoumbos N (2004) Increased serum CA-15.3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency. Oncology 67(5–6):359–367

    Article  CAS  PubMed  Google Scholar 

  30. Dehaghani AS, Ghiam AF, Hosseini M, Mansouri S, Ghaderi A (2007) Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women. Pathol Oncol Res 13(4):360–364

    Article  CAS  PubMed  Google Scholar 

  31. Zervoudis S, Peitsidis P, Iatrakis G, Panourgias E, Koureas A, Navrozoglou I, Dubois JB (2007) Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results. J BUON 12(4):487–492

    CAS  PubMed  Google Scholar 

  32. Pentheroudakis G, Malamou-Mitsi V, Briasoulis E, Damala K, Vassou A, Vartholomatos G, Kolaitis N, Pavlidis N (2004) The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte–colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy. Cancer 101(8):1767–1775

    Article  CAS  PubMed  Google Scholar 

  33. O’Brien DP, Horgan PG, Gough DB, Skehill R, Grimes H, Given HF (1992) CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients. Ann R Coll Surg Engl 74(1):9–11

    PubMed Central  PubMed  Google Scholar 

  34. Geraghty JG, Coveney EC, Sherry F, O’Higgins NJ, Duffy MJ (1992) CA 15-3 in patients with locoregional and metastatic breast carcinoma. Cancer 70(12):2831–2834

    Article  CAS  PubMed  Google Scholar 

  35. Gion M, Mione R, Leon AE, Lüftner D, Molina R, Possinger K, Robertson JF (2001) CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 37(3):355–363

    Article  CAS  PubMed  Google Scholar 

  36. O’Brien DP, Gough DB, Skehill R, Grimes H, Given HF (1994) Simple method for comparing reliability of two serum tumour markers in breast carcinoma. J Clin Pathol 47(2):134–137

    Article  PubMed Central  PubMed  Google Scholar 

  37. Giovanella L, Ceriani L, Giardina G, Bardelli D, Tanzi F, Garancini S (2002) Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Clin Chem Lab Med 40(3):298–303

    Article  CAS  PubMed  Google Scholar 

  38. Nakata B, Ogawa Y, Ishikawa T, Ikeda K, Kato Y, Nishino H, Hirakawa K (2000) SerumCYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 89(6):1285–1290

    Article  CAS  PubMed  Google Scholar 

  39. Nakata B, Takashima T, Ogawa Y, Ishikawa T, Hirakawa K (2004) Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br J Cancer 91(5):873–878

    PubMed Central  CAS  PubMed  Google Scholar 

  40. van Dalen A (1996) Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease. Anticancer Res 16(4B):2345–2349

    PubMed  Google Scholar 

  41. Kawaguchi H, Ohno S, Miyazaki M, Hashimoto K, Egashira A, Saeki H, Watanabe M, Sugimachi K (2000) CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer 89(7):1413–1417

    Article  CAS  PubMed  Google Scholar 

  42. Berglund A, Molin D, Larsson A, Einarsson R, Glimelius B (2002) Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma. Ann Oncol 13(9):1430–1437

    Article  CAS  PubMed  Google Scholar 

  43. Ecke TH, Schlechte HH, Schulze G, Lenk SV, Loening SA (2005) Four tumour markers for urinary bladder cancer–tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation. Anticancer Res 25(1B):635–641

    CAS  PubMed  Google Scholar 

  44. D’Alessandro R, Roselli M, Ferroni P, Mariotti S, Spila A, Aloe S, Carone MD, Abbolito MR, Carlini S, Perri P, Ricciotti A, Botti C, Conti F, Vici P, Chiappetta NR, Cognetti F, Buonomo O, Guadagni F (2001) Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer. Breast Cancer Res Treat 68(1):9–19

    Article  PubMed  Google Scholar 

  45. Barak V, Goike H, Panaretakis KW, Einarsson R (2004) Clinical utility of cytokeratins as tumor markers. Clin Biochem 37(7):529–540

    Article  CAS  PubMed  Google Scholar 

  46. Nakayama M, Satoh H, Ishikawa H, Fujiwara M, Kamma H, Ohtsuka M, Sekizawa K (2003) Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases. Chest 123(6):2001–2006

    Article  CAS  PubMed  Google Scholar 

  47. Nakahama H, Tanaka Y, Fujita Y, Fujii M, Sugita M (1998) CYFRA 21-1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients. Respirology 3(3):207–210

    Article  CAS  PubMed  Google Scholar 

  48. Sarandakou A, Protonotariou E, Rizos D (2007) Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 44(2):151–178

    Article  CAS  PubMed  Google Scholar 

  49. Gonzalez-Quintela A, Mallo N, Mella C, Campos J, Perez LF, Lopez-Rodriguez R, Tome S, Otero E (2006) Serum levels of cytokeratin-18 (tissue polypeptide-specific antigen) in liver diseases. Liver Int 26(10):1217–1224

    Article  CAS  PubMed  Google Scholar 

  50. Nicolini A, Colombini C, Luciani L, Carpi A, Giuliani L (1991) Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer 64(1):154–158

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Vizcarra E, Lluch A, Cibrián R, Jarque F, Alberola V, Belloch V, García-Conde J (1996) Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Res Treat 37(3):209–216

    Article  CAS  PubMed  Google Scholar 

  52. Correale M, Reshkin S, Tedone T, Abbate I, Mangia A, Schittulli F, Paradiso A (1996) Cytokeratins and proliferation in breast cancer patients. Int J Oncol 9(5):1007–1012

    CAS  PubMed  Google Scholar 

  53. Bonfrer JM, Korse CM (1999) TPA and CA 15.3 measurements for breast cancer monitoring in a routine setting. Int J Biol Markers 14(1):40–44

    CAS  PubMed  Google Scholar 

  54. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V (1994) Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 271(20):1593–1597

    Article  CAS  PubMed  Google Scholar 

  55. Smith TJ, Davidson NE, Schapira DV, Grunfeld E, Muss HB, Vogel VG 3rd, Somerfield MR (1999) American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 17(3):1080–1082

    CAS  PubMed  Google Scholar 

  56. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR, American Society of Clinical Oncology Tumor Markers Expert Panel (2001) 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19(6):1865–1878. Erratum in: J Clin Oncol 2001 Nov 1;19(21):4185–4188, J Clin Oncol 2002 Apr 15;20(8):2213

    Google Scholar 

  57. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr, American Society of Clinical Oncology (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312

    Article  CAS  PubMed  Google Scholar 

  58. Pestolazzi BC, Lupoeai-Gely E, Jost LM, Bergh J (2005) ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol 16:157–159

    Google Scholar 

  59. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ, 10th St. Gallen conference. (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18(7):1133–1144. Erratum in: Ann Oncol 2007 Nov;18(11):1917

    Google Scholar 

  60. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

  61. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP, National Academy of Clinical Biochemistry (2008) National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54(12):e11–e79

    Article  CAS  PubMed  Google Scholar 

  62. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P (2005) Tumor markers in breast cancer – European Group on Tumor Markers recommendations. Tumour Biol 26(6):281–293

    Article  PubMed  Google Scholar 

  63. Sölétormos G, Schiøler V, Nielsen D, Skovsgaard T, Dombernowsky P (1993) Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin Chem 39(10):2077–2083

    PubMed  Google Scholar 

  64. Lumachi F, Brandes AA, Boccagni P, Polistina F, Favia G, D’Amico DF (1999) Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3. Anticancer Res 19(5C):4485–4489

    CAS  PubMed  Google Scholar 

  65. Jäger W, Kissing A, Cilaci S, Melsheimer R, Lang N (1994) Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases? Br J Cancer 70(3):493–495

    Article  PubMed Central  PubMed  Google Scholar 

  66. Molina R, Zanón G, Filella X, Moreno F, Jo J, Daniels M, Latre ML, Giménez N, Pahisa J, Velasco M et al (1995) Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 36(1):41–48

    Article  CAS  PubMed  Google Scholar 

  67. Nicolini A, Carpi A (2000) Postoperative follow-up of breast cancer patients: overview and progress in the use of tumor markers. Tumour Biol 21(4):235–248

    Article  CAS  PubMed  Google Scholar 

  68. Sölétormos G, Nielsen D, Schiøler V, Skovsgaard T, Dombernowsky P (1996) Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Chem 42(4):564–575

    PubMed  Google Scholar 

  69. Robertson JF, Jaeger W, Syzmendera JJ, Selby C, Coleman R, Howell A, Winstanley J, Jonssen PE, Bombardieri E, Sainsbury JR, Gronberg H, Kumpulainen E, Blamey RW (1999) The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Eur J Cancer 35(1):47–53

    Article  CAS  PubMed  Google Scholar 

  70. Williams MR, Turkes A, Pearson D, Twining P, Griffiths K, Blamey RW (1999) The use of serum carcinoembryonic antigen to assess therapeutic response in locally advanced and metastatic breast cancer. A prospective study with external review. Eur J Surg Oncol 14:417–422

    Google Scholar 

  71. Sölétormos G, Hyltoft Petersen P, Dombernowsky P (2000) Progression criteria for cancer antigen 15.3 and carcinoembryonic antigen in metastatic breast cancer compared by computer simulation of marker data. Clin Chem 46(7):939–949

    PubMed  Google Scholar 

  72. Quayle JB (1982) Tumour lysis as a factor affecting blood levels of CEA. Br J Cancer 46(2):213–219

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Yasasever V, Dinçer M, Camlica H, Karaloğlu D, Dalay N (1997) Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on “spiking” phenomena. Clin Biochem 30(1):53–56

    Article  CAS  PubMed  Google Scholar 

  74. Sölétormos G, Petersen PH, Dombernowsky P (2000) Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer. Clin Chem Lab Med 38(5):453–463

    Article  PubMed  Google Scholar 

  75. Nicolini A, Ferrari P, Sagripanti A, Carpi A (1999) The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Br J Cancer 79(9–10):1443–1447

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  76. Nicolini A, Carpi A, Ferrari P, Anselmi L, Spinelli C, Conte M, Miccoli P (2000) The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer. Br J Cancer 83(11):1412–1417

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  77. Nicolini A, Fancelli S, Ferrari P, Anselmi L (2012) Reducing radiological imaging during post-operative monitoring of breast cancer patients with serum CEA-TPA-CA15.3 tumor marker (TM) panel and an individual reference limit (IRL). In: Proceedings of the 26th international congress and exhibition of Computer Assisted Radiology and Surgery (CARS), vol 7, Suppl 1:S243

    Google Scholar 

  78. Thompson JA, Pande H, Paxton RJ, Shively L, Padma A, Simmer RL, Todd CW, Riggs AD, Shively JE (1987) Molecular cloning of a gene belonging to the carcinoembryonic antigen gene family and discussion of a domain model. Proc Natl Acad Sci U S A 84(9):2965–2969

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  79. Cases A, Filella X, Molina R, Ballesta AM, Lopez-Pedret J, Revert L (1991) Tumor markers in chronic renal failure and hemodialysis patients. Nephron 57(2):183–186

    Article  CAS  PubMed  Google Scholar 

  80. Collazos J, Genollà J, Ruibal A (1992) Evaluation of the behavior of carcinoembryonic antigen in cirrhotic patients. Int J Biol Markers 7(4):244–248

    CAS  PubMed  Google Scholar 

  81. Amino N, Kuro R, Yabu Y, Takai SI, Kawashima M, Morimoto S, Ichihara K, Miyai K, Kumahara Y (1981) Elevated levels of circulating carcinoembryonic antigen in hypothyroidism. J Clin Endocrinol Metab 52(3):457–462

    Article  CAS  PubMed  Google Scholar 

  82. Shapiro M, Scapa E (2000) Elevated carcinoembryonic antigen (CEA) levels in a patient with no malignancy. Hepatogastroenterology 47(31):163–164

    CAS  PubMed  Google Scholar 

  83. Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T (2008) Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol 13(5):447–451

    Article  CAS  PubMed  Google Scholar 

  84. Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, Colleoni M, Thürlimann B, Mendiola C, Aebi S, Price KN, Pagani O, Simoncini E, Castiglione Gertsch M, Gelber RD, Coates AS, Goldhirsch A (2007) CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol 18(4):701–708

    Article  CAS  PubMed  Google Scholar 

  85. Kokko R, Holli K, Hakama M (2002) Ca 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer 38(9):1189–1193

    Article  CAS  PubMed  Google Scholar 

  86. Given M, Scott M, Mc Grath JP, Given HF (2000) The predictive of tumour markers CA 15-3, TPS and CEA in breast cancer recurrence. Breast 9(5):277–280

    Article  CAS  PubMed  Google Scholar 

  87. Lumachi F, Brandes AA, Ermani M, Bruno G, Boccagni P (2000) Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors. Anticancer Res 20(6C):4751–4755

    CAS  PubMed  Google Scholar 

  88. Jäger W, Krämer S, Palapelas V, Norbert L (1995) Breast cancer and clinical utility of CA 15-3 and CEA. Scand J Clin Lab Invest Suppl 221:87–92

    Article  PubMed  Google Scholar 

  89. Bahrami A, Mortazavizadeh MR, Yazdi MF, Chamani M (2012) Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients. East Mediterr Health J 18(10):1055–1059

    CAS  PubMed  Google Scholar 

  90. Briasoulis E, Andreopoulou E, Tolis CF, Bairaktari E, Katsaraki A, Dimopoulos MA, Fountzilas G, Seferiadis C, Pavlidis N (2001) G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. Cancer 91(5):909–917

    Article  CAS  PubMed  Google Scholar 

  91. Bieglmayer C, Szepesi T, Neunteufel W (1988) Follow-up of metastatic breast cancer patients with a mucin-like carcinoma-associated antigen: comparison to CA 15.3 and carcinoembryonic antigen. Cancer Lett 42(3):199–206

    Article  CAS  PubMed  Google Scholar 

  92. Sölétormos G, Nielsen D, Schiøler V, Skovsgaard T, Winkel P, Mouridsen HT, Dombernowsky P (1993) A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. Ann Oncol 4(10):861–869

    PubMed  Google Scholar 

  93. Pectasides D, Pavlidis N, Gogou L, Antoniou F, Nicolaides C, Tsikalakis D (1996) Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients. Am J Clin Oncol 19(5):459–464

    Article  CAS  PubMed  Google Scholar 

  94. Vizcarra E, Lluch A, Cibrián R, Jarque F, García-Conde J (1994) CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse. Oncology 51(6):491–496

    Article  CAS  PubMed  Google Scholar 

  95. Yildiz M, Oral B, Bozkurt M, Cobaner A (2004) Relationship between bone scintigraphy and tumor markers in patients with breast cancer. Ann Nucl Med 18(6):501–505

    Article  PubMed  Google Scholar 

  96. Begić A, Kucukalić-Selimović E, Obralić N, Durić O, Lacević N, Skopljak A (2006) Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma. Bosn J Basic Med Sci 6(1):75–77

    PubMed  Google Scholar 

  97. Gedik GK, Kiratli PO, Tascioglu B, Aras T (2006) Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma. Saudi Med J 27(3):317–322

    PubMed  Google Scholar 

  98. Zissimopoulos A, Matthaios D, Matthaiou E, Mantadakis E, Karaitianos I (2007) Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients. J BUON 12(4):505–511

    CAS  PubMed  Google Scholar 

  99. Mohammadzadeh M, Alikhah H, Zareh AG (2010) Comparison of bone scan with carbohydrate antigen 15-3 for evaluation of bone metastasis of breast cancer. Pak J Biol Sci 13(4):175–179

    Article  CAS  PubMed  Google Scholar 

  100. Liska V, Holubec L Jr, Treska V, Vrzalova J, Skalicky T, Sutnar A, Kormunda S, Bruha J, Vycital O, Finek J, Pesta M, Pecen L, Topolcan O (2011) Evaluation of tumour markers as differential diagnostic tool in patients with suspicion of liver metastases from breast cancer. Anticancer Res 31(4):1447–1451

    PubMed  Google Scholar 

  101. Evangelista L, Baretta Z, Vinante L, Cervino AR, Gregianin M, Ghiotto C, Bozza F, Saladini G (2011) Could the serial determination of Ca15.3 serum improve the diagnostic accuracy of PET/CT?: results from small population with previous breast cancer. Ann Nucl Med 25(7):469–477

    Article  CAS  PubMed  Google Scholar 

  102. Nakamura T, Kimura T, Umehara Y, Suzuki K, Okamoto K, Okumura T, Morizumi S, Kawabata T (2005) Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery. Surg Today 35(1):19–21

    Article  CAS  PubMed  Google Scholar 

  103. Nicolini A, Carpi A, Ferrari P, Pieri L (2003) Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations. Tumour Biol 24(6):275–280

    Article  CAS  PubMed  Google Scholar 

  104. Nicolini A, Anselmi L, Michelassi C, Carpi A (1997) Prolonged survival by ‘early’ salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer 76(8):1106–1111

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  105. Nicolini A, Carpi A, Michelassi C, Spinelli C, Conte M, Miccoli P, Fini M, Giardino R (2003) “Tumour marker guided” salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. Biomed Pharmacother 57(10):452–459

    Article  CAS  PubMed  Google Scholar 

  106. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, ESMO Guidelines Working Group (2012) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii11–vii19

    Article  PubMed  Google Scholar 

  107. Schöndorf T, Hoopmann M, Warm M, Neumann R, Thomas A, Göhring UJ, Eisberg C, Mallmann P (2002) Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastases receiving trastuzumab therapy predict the clinical course. Clin Chem 48(8):1360–1362

    PubMed  Google Scholar 

  108. British Association of Surgical Oncology Guidelines (1999) The management of metastatic bone disease in the United Kingdom. The Breast Specialty Group of the British Association of Surgical Oncology. Eur J Surg Oncol 25(1):3–23

    Article  Google Scholar 

  109. Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe DW (1988) Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 48(14):4107–4112

    CAS  PubMed  Google Scholar 

  110. Robertson JF, Whynes DK, Dixon A, Blamey RW (1995) Potential for cost economies in guiding therapy in patients with metastatic breast cancer. Br J Cancer 72(1):174–177

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  111. Iwase H, Kobayashi S, Itoh Y, Fukuoka H, Kuzushima T, Iwata H, Yamashita T, Naitoh A, Itoh K, Masaoka A (1995) Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer. Breast Cancer Res Treat 33(1):83–88

    Article  CAS  PubMed  Google Scholar 

  112. http://www.eortc.be/recist/

  113. Lumachi F, Ermani M, Brandes AA, Basso S, Basso U, Boccagni P (2001) Predictive value of different prognostic factors in breast cancer recurrences: multivariate analysis using a logistic regression model. Anticancer Res 21(6A):4105–4108

    CAS  PubMed  Google Scholar 

  114. Duffy MJ (2006) Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52(3):345–351

    Article  CAS  PubMed  Google Scholar 

  115. Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, D’Alessandro R, Carone MD, Cicchetti A, Ricciotti A, Venturo I, Perri P, Di Filippo F, Cognetti F, Botti C, Roselli M (2001) A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 7(8):2357–2362

    CAS  PubMed  Google Scholar 

  116. De La Lande B, Hacene K, Floiras JL, Alatrakchi N, Pichon MF (2002) Prognostic value of CA 15.3 kinetics for metastatic breast cancer. Int J Biol Markers 17(4):231–238

    Google Scholar 

  117. Schuurman JJ, Bong SB, Einarsson R (1996) Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients. Anticancer Res 16(4B):2169–2172

    CAS  PubMed  Google Scholar 

  118. Willsher PC, Beaver J, Blamey RW, Robertson JF (1995) Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA. Anticancer Res 15(4):1609–1611

    CAS  PubMed  Google Scholar 

  119. Kim HS, Park YH, Park MJ, Chang MH, Jun HJ, Kim KH, Ahn JS, Kang WK, Park K, Im YH (2009) Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat 118(1):89–97

    Article  CAS  PubMed  Google Scholar 

  120. Dixon AR, Price MR, Hand CW, Sibley PE, Selby C, Blamey RW (1993) Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer – a comparison with CA15.3. Br J Cancer 68(5):947–949

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  121. Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, Stieber P (2007) Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res 27(4A):1963–1968

    CAS  PubMed  Google Scholar 

  122. Sölétormos G, Nielsen D, Schiøler V, Skovsgaard T, Dombernowsky P (1992) Carbohydrate antigen 549 in metastatic breast cancer during cytostatic treatment and follow-up. Eur J Cancer 28A(4–5):845–850

    Article  PubMed  Google Scholar 

  123. Cheung KL, Robertson FR (2003) Objective measurement of remission and progression in metastatic breast cancer by the use of serum tumour markers. Minerva Chir 58(3):297–303

    CAS  PubMed  Google Scholar 

  124. Kurebayashi J, Yamamoto Y, Tanaka K, Kohno N, Kurosumi M, Moriya T, Nishimura R, Ogawa Y, Taguchi T, Tumor Marker Study Group of the Japanese Breast Cancer Society, Japan (2003) Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: a large-scale retrospective study. Breast Cancer 10(1):38–44

    Article  PubMed  Google Scholar 

  125. Kurebayashi J, Nishimura R, Tanaka K, Kohno N, Kurosumi M, Moriya T, Ogawa Y, Taguchi T (2004) Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study. Breast Cancer 11(4):389–395

    Article  PubMed  Google Scholar 

  126. Yonemori K, Katsumata N, Noda A, Uno H, Yunokawa M, Nakano E, Kouno T, Shimizu C, Ando M, Tamura K, Takeuchi M, Fujiwara Y (2008) Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer. J Cancer Res Clin Oncol 134(11):1199–1206

    Article  CAS  PubMed  Google Scholar 

  127. Sonoo H, Kurebayashi J (1996) Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer. Surg Today 26(4):250–257

    Article  CAS  PubMed  Google Scholar 

  128. Sjöström J, Alfthan H, Joensuu H, Stenman UH, Lundin J, Blomqvist C (2001) Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer. Scand J Clin Lab Invest 61(6):431–441

    Article  PubMed  Google Scholar 

  129. Sölétormos G, Duffy MJ, Hayes DF, Sturgeon CM, Barak V, Bossuyt PM, Diamandis EP, Gion M, Hyltoft-Petersen P, Lamerz RM, Nielsen DL, Sibley P, Tholander B, Tuxen MK, Bonfrer JM (2013) Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers. Clin Chem 59(1):52–59

    Article  PubMed  CAS  Google Scholar 

  130. Sölétormos G, Schiøler V (2000) Description of a computer program to assess cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen information during monitoring of metastatic breast cancer. Clin Chem 46(8 Pt 1):1106–1113

    PubMed  Google Scholar 

  131. Krishnamurthy S (2012) The emerging role of circulating tumor cells in breast cancer. Cancer Cytopathol 120(3):161–166

    Article  CAS  PubMed  Google Scholar 

  132. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781–791

    Article  CAS  PubMed  Google Scholar 

  133. Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, Valero V, Fritsche HA, Cristofanilli M (2012) Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. Int J Cancer 130(7):1590–1597

    Article  CAS  PubMed  Google Scholar 

  134. Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, DETECT Study Group (2012) Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Cancer Res 14(4):R118

    Article  Google Scholar 

  135. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM, Krishnamurthy S (2012) Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 13(7):688–695

    Article  PubMed  Google Scholar 

  136. Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, Rao SB, Eng-Wong J, Seillier-Moiseiwitsch F, Noone AM, Isaacs C (2009) Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 27(31):5153–5159

    Article  PubMed  Google Scholar 

  137. Banys M, Müller V, Melcher C, Aktas B, Kasimir-Bauer S, Hagenbeck C, Hartkopf A, Fehm T (2013) Circulating tumor cells in breast cancer. Clin Chim Acta 423:39–45

    Article  CAS  PubMed  Google Scholar 

  138. Ross JS, Slodkowska EA (2009) Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol 132(2):237–245

    Article  CAS  PubMed  Google Scholar 

  139. Alix-Panabières C, Müller V, Pantel K (2007) Current status in human breast cancer micrometastasis. Curr Opin Oncol 19(6):558–563

    Article  PubMed  Google Scholar 

  140. Lacroix M (2006) Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 13(4):1033–1067

    Article  CAS  PubMed  Google Scholar 

  141. Riethdorf S, Pantel K (2008) Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology 75(2):140–148

    Article  PubMed  Google Scholar 

  142. Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4(6):448–456

    Article  CAS  PubMed  Google Scholar 

  143. Wölfle U, Müller V, Pantel K (2006) Disseminated tumor cells in breast cancer: detection, characterization and clinical relevance. Future Oncol 2(4):553–561

    Article  PubMed  Google Scholar 

  144. Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, Pantel K, Solomayer E (2006) A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107(5):885–892

    Article  PubMed  Google Scholar 

  145. Schoenfeld A, Kruger KH, Gomm J, Sinnett HD, Gazet JC, Sacks N, Bender HG, Luqmani Y, Coombes RC (1997) The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur J Cancer 33(6):854–861

    Article  CAS  PubMed  Google Scholar 

  146. Smith BM, Slade MJ, English J, Graham H, Lüchtenborg M, Sinnett HD, Cross NC, Coombes RC (2000) Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol 18(7):1432–1439

    CAS  PubMed  Google Scholar 

  147. Zhong XY, Kaul S, Lin YS, Eichler A, Bastert G (2000) Sensitive detection of micrometastases in bone marrow from patients with breast cancer using immunomagnetic isolation of tumor cells in combination with reverse transcriptase/polymerase chain reaction for cytokeratin-19. J Cancer Res Clin Oncol 126(4):212–218

    Article  CAS  PubMed  Google Scholar 

  148. Bossolasco P, Ricci C, Farina G, Soligo D, Pedretti D, Scanni A, Deliliers GL (2002) Detection of micrometastatic cells in breast cancer by RT-pCR for the mammaglobin gene. Cancer Detect Prev 26(1):60–63

    Article  CAS  PubMed  Google Scholar 

  149. Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M (2005) Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer 92(5):906–912

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  150. Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpé S, Van Marck E, Vermeulen PB, Dirix LY (2006) Prognostic significance of disseminated tumor cells as detected by quantitative real-time reverse-transcriptase polymerase chain reaction in patients with breast cancer. Clin Breast Cancer 7(2):146–152

    Article  CAS  PubMed  Google Scholar 

  151. Alix-Panabières C (2012) EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Recent Results Cancer Res 195:69–76

    Article  PubMed  Google Scholar 

  152. Berois N, Varangot M, Sóñora C, Zarantonelli L, Pressa C, Laviña R, Rodríguez JL, Delgado F, Porchet N, Aubert JP, Osinaga E (2003) Detection of bone marrow-disseminated breast cancer cells using an RT-PCR assay of MUC5B mRNA. Int J Cancer 103(4):550–555

    Article  CAS  PubMed  Google Scholar 

  153. Bölke E, Orth K, Gerber PA, Lammering G, Mota R, Peiper M, Matuschek C, Budach W, Rusnak E, Shaikh S, Dogan B, Prisack HB, Bojar H (2009) Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients. Eur J Med Res 14(8):359–363

    PubMed Central  PubMed  Google Scholar 

  154. Braun S, Pantel K, Müller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmüller G, Schlimok G (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342(8):525–533

    Article  CAS  PubMed  Google Scholar 

  155. Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jäger W (2001) Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 19(16):3669–3674

    CAS  PubMed  Google Scholar 

  156. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793–802

    Article  CAS  PubMed  Google Scholar 

  157. Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K (2005) The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 103(5):884–891

    Article  PubMed  Google Scholar 

  158. Wiedswang G, Borgen E, Kåresen R, Qvist H, Janbu J, Kvalheim G, Nesland JM, Naume B (2004) Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 10(16):5342–5348

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Transplantations and New Technologies in Medicine, University of Pisa, Pisa, Italy

    Andrea Nicolini & Paola Ferrari

  2. Unit of Epidemiology and Biostatistics, National Council of Research, Pisa, Italy

    Giuseppe Rossi

Authors
  1. Andrea Nicolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paola Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Nicolini .

Editor information

Editors and Affiliations

  1. Institute of Biochemistry and Clinical B, Catholic University School of Medicine, Rome, Italy

    Roberto Scatena

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Nicolini, A., Ferrari, P., Rossi, G. (2015). Mucins and Cytokeratins as Serum Tumor Markers in Breast Cancer. In: Scatena, R. (eds) Advances in Cancer Biomarkers. Advances in Experimental Medicine and Biology, vol 867. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7215-0_13

Download citation

Publish with us

Policies and ethics

Search

Navigation